Welcome to our dedicated page for Beam Therapeutics SEC filings (Ticker: BEAM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beam Therapeutics Inc. filings document the regulatory record for a Nasdaq-listed biotechnology company developing base-editing genetic medicines. Its Form 8-K reports cover operating results, portfolio updates, senior secured credit facility terms, license and standby license arrangements for base-editing patent rights, board changes and Regulation FD presentations.
Proxy materials describe annual meeting matters, director elections, executive compensation, equity awards and stockholder voting procedures. The filings also identify Beam’s common stock, capital structure, material agreements and governance practices tied to its clinical-stage biotechnology business.
Beam Therapeutics Inc. reported that its Chief Medical Officer, Simon Amy, received a new stock option grant. On January 31, 2026, Simon Amy was awarded a stock option to buy 88,500 shares of Beam common stock at an exercise price of $27.62 per share, expiring on January 31, 2036. The option was granted at no cost to receive it and will vest in equal monthly installments over 48 months, contingent on continued service with Beam Therapeutics through each vesting date.
John M Evans has filed a notice to sell 25,000 shares of BEAM common stock on the NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services. The planned sale has an aggregate market value of $708,947.50, with 101,474,944 shares outstanding.
The 25,000 shares to be sold were acquired on January 30, 2026 via a stock option exercise from the issuer, paid in cash on the same date. During the past three months, Evans also sold 25,000 common shares on January 29, 2026 for gross proceeds of $734,582.50.
Beam Therapeutics filed a Form 144 notice for a planned insider stock sale. The filing covers a proposed sale of 25,000 shares of common stock with an aggregate market value of $734,582.50 through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 01/29/2026.
The 25,000 shares were acquired on 01/29/2026 by exercising stock options directly from the issuer and paid for in cash. Shares of Beam Therapeutics outstanding were 101,474,944 at the time referenced, providing a baseline for the size of this planned sale.
Bethany J. Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics Inc., sold 6,198 shares of common stock on January 22, 2026 at a weighted average price of $35.0005 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 19, 2025. After this transaction, she directly owns 34,813 shares of Beam Therapeutics common stock.
Beam Therapeutics Chief Legal Officer Christine Bellon sold 1,371 shares of Beam Therapeutics common stock at $34 per share on January 22, 2026, under a Rule 10b5-1 trading plan. After this planned sale, she directly beneficially owned 95,667 shares of the company’s common stock. The trading plan was adopted by the reporting person on September 16, 2025, indicating the sale was executed pursuant to a pre-arranged schedule rather than a discretionary, same-day decision.
Beam Therapeutics insider plans additional stock sale under Rule 144. A holder intends to sell 1,371 shares of Beam common stock through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of 46,614.00. The approximate sale date is 01/22/2026, and 101,474,944 shares of common stock were outstanding at the time referenced.
The shares to be sold were acquired as restricted stock from the issuer on three dates in 2024, totaling 1,371 shares. Over the past three months, the same seller, Christine Bellon, has already sold 18,629 shares of common stock for gross proceeds of 644,830.68 and 1,254 shares for 33,978.85. The form includes a representation that the seller is not aware of undisclosed material adverse information about Beam’s operations.
Beam Therapeutics Inc. senior vice president of finance and treasurer Bethany J. Cavanagh reported a planned sale of company stock. On January 20, 2026, she sold 3,034 shares of Common Stock of Beam Therapeutics at a price of $30.12 per share, leaving her with 41,011 shares beneficially owned directly after the transaction. The sale was carried out under a Rule 10b5-1 trading plan that she adopted on September 19, 2025, which means the trades were pre-arranged according to preset instructions rather than made at her discretion on the trade date.
Beam Therapeutics Inc. Chief Legal Officer Christine Bellon reported sales of company common stock in open-market transactions on January 15, 2026, executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 16, 2025.
She sold blocks of Beam common stock at weighted-average prices of $33.6219, $34.7182 and $35.3988, with each price reflecting multiple trades within disclosed ranges. Following these sales, Bellon directly beneficially owned 97,038 shares of Beam common stock.
Christine Bellon filed a Rule 144 notice for the planned sale of 18,629 shares of BEAM common stock through Morgan Stanley Smith Barney LLC on NASDAQ. The shares to be sold have an aggregate market value of $644,830.69, while 101,474,944 shares of common stock are reported as outstanding. The filing lists these shares as common stock awards acquired as restricted stock from the issuer between March 31, 2022 and March 31, 2024. It also notes that in the previous three months, Bellon sold 1,254 common shares on January 2, 2026 for gross proceeds of $33,978.85. The approximate date for the new sale is January 15, 2026.
Beam Therapeutics Inc. reported in a current update that it estimates having approximately $1.25 billion in cash, cash equivalents and marketable securities as of December 31, 2025. This figure is preliminary, unaudited and may change as the company completes its year-end closing and prepares full financial statements, so the company cautions against placing undue reliance on the estimate.
Beam also highlighted progress across its base editing portfolio and described key anticipated milestones in a press release and updated corporate presentation furnished as exhibits. These materials will support upcoming conference appearances, including an investor presentation at the 44th Annual J.P. Morgan Healthcare Conference.